Novel specific activity-based probes validate KLK proteases as druggable targets

References

• Lee KY, Chau CH, Price DK, Figg WD. Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activome. Cancer Biol Ther. 2022;23(1):136–138. doi:10.1080/15384047.2022.2033059.
   PubMed Web of Science ®Google Scholar
• Lovell S, Zhang L, Kryza T, Neodo A, Bock N, De Vita E, Williams ED, Engelsberger E, Xu C, Bakker AT, et al. A suite of activity-based probes to dissect the KLK activome in drug-resistant prostate cancer. J Am Chem Soc. 2021;143(23):8911–8924. doi:10.1021/jacs.1c03950.
   PubMed Web of Science ®Google Scholar
• Bisyris E, Zingkou E, Kordopati GG, Matsoukas M, Magriotis PA, Pampalakis G, Sotiropoulou G. A novel theranostic activity-based probe targeting kallikrein 7 for the diagnosis and treatment of skin diseases. Chem Commun. 2021;57(53):6507–6510. doi:10.1039/d1cc01673c.
   PubMed Web of Science ®Google Scholar
• Bisyris E, Zingkou E, Kordopati GG, Matsoukas M, Magriotis PA, Pampalakis G, Sotiropoulou G. Generation of a quenched phosphonate activity-based probe for labelling the active KLK7 protease. Org Biomol Chem. 2021;19(31):6834–6841. doi:10.1039/d1ob01273h.
   PubMed Web of Science ®Google Scholar
• Zingkou E, Pampalakis G, Sotiropoulou G. Cocktails of KLK5 protease inhibitors and anti-TNFα therapeutics: an effective treatment for Netherton syndrome. J Clin Immunol. 2022;42(3):597–605. doi:10.1007/s10875-021-01195-0.
   PubMed Web of Science ®Google Scholar
• Furio L, Pampalakis G, Michael IP, Nagy A, Sotiropoulou G, Hovnanian A. KLK5 inactivation reverses cutaneous hallmarks of Netherton syndrome. PLoS Genet. 2015;11(9):e1005389. doi:10.1371/journal.pgen.1005389.
   PubMed Web of Science ®Google Scholar
• Kasparek P, Ileninova Z, Zbodakova O, Kanchev I, Benada O, Chalupsky K, Brattsand M, Beck IM, Sedlacek R. KLK5 and KLK7 ablation fully rescues lethality of Netherton syndrome-like phenotype. PLoS Genet. 2017; 13(1):e1006566. doi:10.1371/journal.pgen.1006566.
   PubMed Web of Science ®Google Scholar
• Liddle J, Beneton V, Benson M, Bingham R, Bouillot A, Boullay AB, Brook E, Cryan J, Denis A, Edgar E, et al. A potent and selective kallikrein-5 inhibitor delivers high pharmacological activity in skin from patients with Netherton syndrome. J Invest Dermatol. 2021;141(9):2272–2279. doi:10.1016/j.jid.2021.01.029.
   PubMed Web of Science ®Google Scholar
• Ben-Nun Y, Merquiol E, Brandis A, Turk B, Scherz A, Blum G. Photodynamic quenched cathepsin activity-based probes for cancer detection and macrophage targeted therapy. Theranostics. 2015;5(8):847–862. doi:10.7150/thno.10854.
   PubMed Web of Science ®Google Scholar
• Weiss-Sadan T, Ben-Nun Y, Maimoun D, Merquiol E, Abd-Elrahman I, Gotsman I, Blum G. A theranostic activity-based probe for noninvasive intervention in cardiovascular diseases. Theranostics. 2019;9(20):5731–5738. doi:10.7150/thno.34402.
   PubMed Web of Science ®Google Scholar
• Hannu K, Johanna M, Ulf-Håkan S. KLK-targeted therapies for prostate cancer. Ejiff. 2014;25(2):207–218.
   PubMedGoogle Scholar
• LeBeau AM, Singh P, Isaacs JT, Denmeade SR. Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen. Chem Biol. 2008;15(7):665–674. doi:10.1016/j.chembiol.2008.05.020.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, et al. . Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099–1105. doi:10.1200/JCO.2009.25.0597.
   PubMed Web of Science ®Google Scholar
• Sotiropoulou G, Pampalakis G. Targeting the kallikrein-related peptidases for drug development. Trends Pharmacol Sci. 2012;33(12):623–634. doi:10.1016/j.tips.2012.09.005.
   PubMed Web of Science ®Google Scholar
• Pampalakis G, Zingkou E, Panagiotis C, Sotiropoulou G. Kallikreins emerge as new regulators of viral infections. Cell Mol Life Sci. 2021;78(21–22):6735–6744. doi:10.1007/s00018-021-03922-7.
   PubMed Web of Science ®Google Scholar
• Pampalakis G, Sotiropoulou G. . Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim Biophys Acta-Rev Cancer. 2007;1776(1):22–31. doi:10.1016/j.bbcan.2007.06.001.
   PubMed Web of Science ®Google Scholar
• Michael IP, Pampalakis G, Mikolajczyk SD, Malm J, Sotiropoulou G, Diamandis EP. Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression. J Biol Chem. 2006;281(18):12743–12750. doi:10.1074/jbc.M600326200.
   PubMed Web of Science ®Google Scholar
• Oikonomopoulou K, Hansen KK, Baruch A, Hollenberg MD, Diamandis EP. Immunofluorometric activity-based probe analysis of active KLK6 in biological fluids. Biol Chem. 2008;389(6):747–756. doi:10.1515/BC.2008.086.
   PubMed Web of Science ®Google Scholar
• Pampalakis G, Zingkou E, Vekrellis K, Sotiropoulou G. “Activography”: a novel, versatile and easily adaptable method for monitoring enzymatic activities in situ. Chem Commun. 2017;53(22):3246–3248. doi:10.1039/c7cc01081h.
   PubMed Web of Science ®Google Scholar
• Zingkou E, Pampalakis G, Kiritsi D, Valari M, Jonca N, Sotiropoulou G. Activography reveals aberrant proteolysis in desquamation diseases of differing genetic backgrounds. Exp Dermatol. 2019;28(1):86–89. doi:10.1111/exd.13832.
   PubMed Web of Science ®Google Scholar
• De Vita E, Schüler P, Lovell S, Lohbeck J, Kullmann S, Rabinovich E, Sananes A, Heßling B, Hamon V, Papo N, et al. . Depsipeptides featuring a neutral P1 are potent inhibitors of kallikrein-related peptidase 6 with on-target cellular activity. J Med Chem. 2018;61(19):8859–8874. doi:10.1021/acs.jmedchem.8b01106.
   PubMed Web of Science ®Google Scholar
• Gruba N, Bielecka W, Wysocka M, Wojtysiak A, Brzezińska-Bodal M, Sychowska K, Kalińska M, Magoch M, Pęcak A, Falkowski K, et al. Development of chemical tools to monitor human kallikrein 13 (KLK13) activity. Int J Mol Sci. 2019;20(7):1557. doi:10.3390/ijms20071557.
   PubMed Web of Science ®Google Scholar
• Kryza T, Bock N, Lovell S, Rockstroh A, Lehman ML, Lesner A, Panchadsaram J, Silva LM, Srinivasan S, Snell CE, et al. The molecular function of kallikrein-related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer. Mol Oncol. 2020;14(1):105–128. doi:10.1002/1878-0261.12587.
   PubMed Web of Science ®Google Scholar
• Sotiropoulou G, Zingkou E, Pampalakis G. . Reconstructing the epidermal proteolytic cascades in health and disease. J Pathol. 2022; in press. doi:10.1002/path.5888.
   PubMed Web of Science ®Google Scholar
• Sotiropoulou G, Zingkou E, Bisyris E, Pampalakis G. . Activity-based probes for proteases pave the way to theranostic applications. Pharmaceutics. 2022;14(5):977. doi:10.3390/pharmaceutics14050977.
   PubMed Web of Science ®Google Scholar